Liquid Chromatographic Determination of Plasma Ropivacaine for Assessing Pharmacokinetics of the Viscous Preparation

DOI 機関リポジトリ Web Site Web Site 被引用文献1件 参考文献31件
  • Kawata Takeshi
    Department of Pharmaceutical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba Faculty of Pharmaceutical Sciences, Josai University
  • Homma Masato
    Department of Pharmaceutical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba Department of Pharmacy, Tsukuba University Hospital
  • Kakiuchi Yoshihiro
    Department of Pharmacy, Tsukuba University Hospital
  • Inomata Shinichi
    Department of Anesthesiology, Graduate School of Comprehensive Human Sciences, University of Tsukuba
  • Miyabe Masayuki
    Department of Anesthesiology, Graduate School of Comprehensive Human Sciences, University of Tsukuba
  • Kobayashi Daisuke
    Faculty of Pharmaceutical Sciences, Josai University
  • Morimoto Yasunori
    Faculty of Pharmaceutical Sciences, Josai University
  • Kohda Yukinao
    Department of Pharmaceutical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba Department of Pharmacy, Tsukuba University Hospital

この論文をさがす

抄録

We developed assay method for determination of plasma ropivacaine by using reversed-phase high performance liquid chromatography (HPLC) equipped with ordinary octadecylsilyl silica-gel (ODS) column. Plasma samples spiked with internal standard (bupivacaine) were treated by ethylacetate to extract ropivacaine and internal standard. The ropivacaine and internal standard separated on ODS column were detected by an ultra violet (UV) detector set at 215 nm. The mobile phase solvent consisted of acetonitrile, methanol and 0.05 M phosphate buffer adjusted to pH 4.0 (10 : 30 : 60, v/v) was pumped at a flow rate of 0.8 ml/min. The calibration curve of ropivacaine was linear at the concentration of 25—1000 ng/ml (r=0.9998). The recoveries of ropivacaine from plasma were greater than 87.9% with the coefficient of variations (CVs) less than 6.1%. The CVs for intra- and inter-day assay of ropivacaine were 2.0—12.0% and 1.7—14.8%, respectively. This HPLC method was applied to determining plasma ropivacaine in two healthy subjects after receiving 0.5% ropivacaine viscous preparation, which was prepared in our hospital. Our preliminary pharmacokinetic data showed that ropivacaine viscous could be used safely based on the plasma ropivacaine concentrations (Cmax: 89—125 ng/ml) for pain relief in oral mucosa.

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (31)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ